Lesson plan

GBP511

GBP511 is a self-assembling protein nanoparticle-based universal coronavirus vaccine candidate developed to provide broad, multivalent protection against the sarbecovirus subgenus, which includes SARS-CoV-2 (the cause of COVID-19), SARS-CoV-1 (the cause of SARS), and various animal-borne coronaviruses with pandemic potential. It was developed through a collaboration between the University of Washington's Institute for Protein Design and the South Korean pharmaceutical company SK Bioscience. GBP511 represents the first vaccine targeting the entire SARS virus family to enter Phase I/II human clinical trials.

Back to article

Article summary

GBP511 is a self-assembling protein nanoparticle-based universal coronavirus vaccine candidate developed to provide broad, multivalent protection against the sarbecovirus subgenus, which includes SARS-CoV-2 (the cause of COVID-19), SARS-CoV-1 (the cause of SARS), and various animal-borne coronaviruses with pandemic potential. It was developed through a collaboration between the University of Washington's Institute for Protein Design and the South Korean pharmaceutical company SK Bioscience. GBP511 represents the first vaccine targeting the entire SARS virus family to enter Phase I/II human clinical trials.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.